Daewoong Pharmaceutical has strengthened its case for global expansion by quantitatively establishing the relationship between the drug action of its Type 2 diabetes treatment, Enblo (ingredient name: Inavogliflozin), and its blood sugar-lowering effects.
The company announced on June 8 that it presented research findings on the correlation between drug exposure and blood sugar reduction for Enblo at the European 2026 PAGE conference held from June 2 to 4.
Enblo, a member of the SGLT-2 inhibitor class, works by inhibiting glucose reabsorption in the kidneys, leading to increased glucose excretion in urine.
The study integrated data from 10 clinical trials involving 224 Korean participants and Phase 3 clinical data from 151 Chinese patients with Type 2 diabetes. It analyzed the quantitative relationship between increased glucose excretion in urine and decreased hemoglobin A1c (HbA1c) levels following Enblo administration, uniquely connecting drug absorption to changes in blood sugar indicators within a single integrated model.
The analysis confirmed a correlation between increased glucose excretion and greater reductions in HbA1c levels following Enblo treatment. Notably, the blood sugar-lowering effects were predicted to remain stable even in patients with impaired kidney function.
Additionally, no significant pharmacokinetic differences were observed between Korean and Chinese patients, confirming the potential for administering the same dosage. Daewoong Pharmaceutical plans to use these research results as a basis for its global approval and indication expansion strategies.
The company is actively pursuing the expansion of Enblo into global markets. In May, it received approvals in seven out of twelve Latin American countries, including Mexico, for product registration.
Na Jae-jin, head of Daewoong Pharmaceutical, stated, "The confirmation of consistent pharmacokinetic characteristics in Chinese patients strengthens our scientific basis for entering the global market. We will solidify the competitiveness of our domestic diabetes new drug, Enblo."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.